|
1
|
Nilsson B, Bümming P, Meis-Kindblom JM,
Odén A, Dortok A, Gustavsson B, Sablinska K and Kindblom LG:
Gastrointestinal stromal tumors: The incidence, prevalence,
clinical course, and prognostication in the preimatinib mesylate
era - a population-based study in western Sweden. Cancer.
103:821–829. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors: Pathology and prognosis at different sites. Semin
Diagn Pathol. 23:70–83. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fletcher CD, Berman JJ, Corless C,
Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti
H, Rubin BP, et al: Diagnosis of gastrointestinal stromal tumors: A
consensus approach. Hum Pathol. 33:459–465. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sorour MA, Kassem MI, Ghazal Ael-H,
El-Riwini MT and Abu Nasr A: Gastrointestinal stromal tumors (GIST)
related emergencies. Int J Surg. 12:269–280. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miettinen M, El Rifai W, H L, Sobin L and
Lasota J: Evaluation of malignancy and prognosis of
gastrointestinal stromal tumors: A review. Hum Pathol. 33:478–483.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rossi S, Miceli R, Messerini L, Bearzi I,
Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A,
Toffolatti L, et al: Natural history of imatinib-naive GISTs: A
retrospective analysis of 929 cases with long-term follow-up and
development of a survival nomogram based on mitotic index and size
as continuous variables. Am J Surg Pathol. 35:1646–1656. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Agaimy A, Vassos N, Wunsch PH, Hohenberger
W, Hartmann A and Croner RS: Impact of serosal
involvement/extramural growth on the risk of synchronous and
metachronous peritoneal spread in gastrointestinal stromal tumors:
Proposal for a macroscopic classification of GIST. Int J Clin Exp
Pathol. 5:12–22. 2012.PubMed/NCBI
|
|
8
|
Panizo-Santos A, Sola I, Vega F, de Alava
E, Lozano MD, Idoate MA and Pardo-Mindán J: Predicting metastatic
risk of gastrointestinal stromal tumors: Role of cell proliferation
and cell cycle regulatory proteins. Int J Surg Pathol. 8:133–144.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tannapfel A and Wittekind C: The current
TNM system for gastrointestinal tumors part II. Pathologe.
31:348–352. 2010.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Illig R, Fritsch H and Schwarzer C:
Breaking the seals: Efficient mRNA detection from human archival
paraffin-embedded tissue. RNA:. 15:1588–1596. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Illig R, Fritsch H and Schwarzer C:
Spatio-temporal expression of HOX genes in human hindgut
development. Dev Dyn. 242:53–66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brainard JA and Goldblum JR: Stromal
tumors of the jejunum and ileum: A clinicopathologic study of 39
cases. Am J Surg Pathol. 21:407–416. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kemmerling R, Stintzing S, Mühlmann J,
Dietze O and Neureiter D: Primary testicular lymphoma: A strictly
homogeneous hematological disease? Oncol Rep. 23:1261–1267.
2010.PubMed/NCBI
|
|
14
|
Kemmerling R, Alinger B, Dietze O,
Bösmüller HC, Ocker M, Wolkersdörfer GW, Berr F, Neureiter D and
Kiesslich T: Association of stem cell marker expression pattern and
survival in human biliary tract cancer. Int J Oncol. 41:511–522.
2012.PubMed/NCBI
|
|
15
|
Kemmerling R, Weyland D, Kiesslich T,
Illig R, Klieser E, Jäger T, Dietze O and Neureiter D: Robust
linear regression model of Ki-67 for mitotic rate in
gastrointestinal stromal tumors. Oncol Lett. 7:745–749.
2014.PubMed/NCBI
|
|
16
|
Kiesslich T, Alinger B, Wolkersdörfer GW,
Ocker M, Neureiter D and Berr F: Active Wnt signalling is
associated with low differentiation and high proliferation in human
biliary tract cancer in vitro and in vivo and is
sensitive to pharmacological inhibition. Int J Oncol. 36:49–58.
2010.PubMed/NCBI
|
|
17
|
Lv A, Li Z, Tian X, Guan X, Zhao M, Dong B
and Hao C: SKP2 high expression, KIT exon 11 deletions, and
gastrointestinal bleeding as predictors of poor prognosis in
primary gastrointestinal stromal tumors. PLoS One. 8:e629512013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Demir L, Ekinci N, Erten C, Kucukzeybek Y,
Alacacioglu A, Somali I, Can A, Dirican A, Bayoglu V, Akyol M, et
al: Does immunohistochemistry provide additional prognostic data in
gastrointestinal stromal tumors? Asian Pac J Cancer Prev.
14:4751–4758. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu LC, Xu WT, Wu X, Zhao P, Lv YL and
Chen L: Overexpression of carbonic anhydrase II and Ki-67 proteins
in prognosis of gastrointestinal stromal tumors. World J
Gastroenterol. 19:2473–2480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qi Y, Zhao W, Wang Z, Li T and Meng X:
Tumor sites and microscopic indicators are independent prognosis
predictors of gastrointestinal stromal tumors. Tohoku J Exp Med.
233:65–72. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rudolph P, Gloeckner K, Parwaresch R,
Harms D and Schmidt D: Immunophenotype, proliferation, DNA ploidy,
and biological behavior of gastrointestinal stromal tumors: A
multivariate clinicopathologic study. Hum Pathol. 29:791–800. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gumurdulu D, Erdogan S, Kayaselcuk F,
Seydaoglu G, Parsak CK, Demircan O and Tuncer I: Expression of
COX-2, PCNA, Ki-67 and p53 in gastrointestinal stromal tumors and
its relationship with histopathological parameters. World J
Gastroenterol. 13:426–431. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fujita A, Yamamoto H, Imamura M, Nakamura
N, Maehara Y, Tsuneyoshi M and Oda Y: Expression level of the
mitotic checkpoint protein and G2-M cell cycle regulators and
prognosis in gastrointestinal stromal tumors in the stomach.
Virchows Arch. 460:163–169. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meara RS, Cangiarella J, Simsir A, Horton
D, Eltoum I and Chhieng DC: Prediction of aggressiveness of
gastrointestinal stromal tumours based on immunostaining with
bcl-2, Ki-67 and p53. Cytopathology. 18:283–289. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
ESMO/European Sarcoma Network Working
Group: Gastrointestinal stromal tumors: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
23(Suppl 7): vii49–vii55. 2012.PubMed/NCBI
|
|
26
|
Emory TS, Sobin LH, Lukes L, Lee DH and
O'Leary TJ: Prognosis of gastrointestinal smooth-muscle (stromal)
tumors: Dependence on anatomic site. Am J Surg Pathol. 23:82–87.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan H, Marchettini P, Acherman YI, Gething
SA, Brun E and Sugarbaker PH: Prognostic assessment of
gastrointestinal stromal tumor. Am J Clin Oncol. 26:221–228. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors: Review on morphology, molecular pathology,
prognosis and differential diagnosis. Arch Pathol Lab Med.
130:1466–1478. 2006.PubMed/NCBI
|
|
29
|
Miettinen M and Lasota J: Histopathology
of gastrointestinal stromal tumor. J Surg Oncol. 104:865–873. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reichardt P and Reichardt A:
Gastrointestinal stromal tumors (GIST). Dtsch Med Wochenschr.
138:2013–2016. 2013.(In German). View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lovell DP: Biological importance and
statistical significance. J Agric Food Chem. 61:8340–8348. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Joensuu H, Vehtari A, Riihimäki J, Nishida
T, Steigen SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi C,
et al: Risk of recurrence of gastrointestinal stromal tumour after
surgery: An analysis of pooled population-based cohorts. Lancet
Oncol. 13:265–274. 2012. View Article : Google Scholar : PubMed/NCBI
|
